Search Results 361-370 of 9009 for Conduction

1. A Study Using Docetaxel with or without MLN1117 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Mayo Clinic

   ... conduction system abnormalities; Fridericia's corrected QT interval > 475 milliseconds (msec) (males) or > 450 msec (females) on a 12-lead ECG during the ...

2. Tachycardia - Symptoms and causes - Mayo Clinic

   https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmias-and-conduction-disorders/overview-of-arrhythmias. Accessed Nov. 22, 2023 ...

3. A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma - Mayo Clinic

   History or presence of clinically significant ventricular arrhythmias, atrial fibrillation, resting bradycardia, or conduction abnormality;; Unstable angina ...

4. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   Conduction abnormality requiring a pacemaker;; Valvular disease with documented compromise in cardiac function; or; Symptomatic pericarditis. History of ...

5. RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations - Mayo Clinic

   ... conduction, or morphology with resting ECG (e.g., complete left-bundle branch block, 3rd-degree heart block); or clinically significant, uncontrolled ...

6. Publications - Maliha Zahid, M.B.B.S., Ph.D. - Mayo Clinic

   2012 Oct; 12(5):374-80. View PubMed; Zahid M, Arora S. Reverse Wenckebach "pseudo-supernormal" conduction or paroxysmal atrioventricular block. J Cardiovasc ...

7. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease - Mayo Clinic

   History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to ...

8. Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

   ... conduction studies. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to ...

9. Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma - Mayo Clinic

   ... conduction system abnormalities; No serious medical or psychiatric illness likely to interfere with participation in this clinical study; No known ...

10. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) - Mayo Clinic

    ... conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant ...